A study comparing the cost-effectiveness of conventional and drug-eluting transarterial chemoembolisation (cTACE and DEB-TACE) for the treatment of hepatocellular carcinoma in an Australian public hospital.
Warren ClementsAbigail ChenowethBenjamin PhippsLowella MozoMark Paul BolgerLaura MorphettTuan PhanJim KoukounarasMatthew W LukiesPublished in: Journal of medical imaging and radiation oncology (2024)
Both cTACE and DEB-TACE are low-cost treatments in Australia. However, DEB-TACE offers a solution with an ICER of AUD$10,560 per QALY gained which is below the Australian government willingness to pay threshold and thus is a more cost-effective treatment.
Keyphrases